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Adipose tissue is now viewed as an endocrine organ because it can secrete adipose-derived hormones called adipokines, 
including leptin, TNF-α (tumor necrosis factor-α), and adipo-
nectin.1 Some of those adipokines influence vasocontractility 
and regulate blood pressure (BP). For example, both leptin and 
TNF-α have been shown to affect both vasodilation and vaso-
constriction.2 Adiponectin is a vasodilator that has been shown 
to increase nitrogen oxide (NO) and inhibits TNF-α production.3 
An adiponectin family paralog, CTRP (C1q/TNF-α–related pro-
tein), has recently been identified.4 CTRP1 (C1q/TNF-α–related 
protein 1) levels are positively correlated with blood glucose 
levels and body mass index5–8; most studies have focused on the 
metabolic functions of CTRP1.9,10 The administration of CTRP1 
lowers blood glucose levels in diabetic mice by enhancing 
AMPK (AMP-activated protein kinase)- and IRS-1 (insulin re-
ceptor substrate 1)–mediated energy consumption11–13; neverthe-
less, plasma or serum levels of CTRP1 are increased in patients 
or animal models of metabolic diseases, such as type II diabetes 
mellitus and obesity.8,14,15 These results suggest that high blood 
glucose levels upregulate CTRP1 levels in an effort to lower 
blood glucose.6,7,16 CTRP1 levels are also increased in the se-
rum of hypertensive patients, and CTRP1 stimulates aldosterone 
production via upregulation of the transcription of cytochrome 
P450 11β-hydroxylase 2 (Cyp11b2), which is the rate-limiting 
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Rationale: Circulating CTRP1 (C1q/TNF-α [tumor necrosis factor-α]–related protein 1) levels are increased in 
hypertensive patients compared with those in healthy subjects. Nonetheless, little is known about the molecular 
and physiological function of CTRP1 in blood pressure (BP) regulation.
Objective: To investigate the physiological/pathophysiological role of CTRP1 in BP regulation.
Methods and Results: CTRP1 production was increased to maintain normotension under dehydration conditions, 
and this function was impaired in inducible CTRP1 KO (knockout) mice (CTRP1ΔCAG). The increase in CTRP1 
under dehydration conditions was mediated by glucocorticoids, and the antagonist mifepristone prevented 
the increase in CTRP1 and attenuated BP recovery. Treatment with a synthetic glucocorticoid increased the 
transcription, translation, and secretion of CTRP1 from skeletal muscle cells. Functionally, CTRP1 increases BP 
through the stimulation of the AT1R (Ang II [angiotensin II] receptor 1)-Rho (Ras homolog gene family)/ROCK 
(Rho kinase)–signaling pathway to induce vasoconstriction. CTRP1 promoted AT1R plasma membrane trafficking 
through phosphorylation of AKT and AKT substrate of 160 kDa (AS160). In addition, the administration of an 
AT1R blocker, losartan, recovered the hypertensive phenotype of CTRP1 TG (transgenic) mice.
Conclusions: For the first time, we provide evidence that CTRP1 contributes to the regulation of BP homeostasis by 
preventing dehydration-induced hypotension.  (Circ Res. 2018;123:e5-e19. DOI: 10.1161/CIRCRESAHA.118.312871.)
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enzyme for aldosterone production.17 CTRP1 is also considered 
to be a novel biomarker for coronary artery18–22 and heart23 dis-
ease because patients with this disease have increased circulat-
ing CTRP1 levels. In addition, CTRP1 has been identified as a 
regulator of vascular function24–26 and as an antiacute ischemic 
injury protection in the heart.27 These accumulating pieces of ev-
idence support the notion that CTRP1 plays an important role in 
the regulation of cardiovascular function. Nonetheless, no physi-
ological or molecular roles for CTRP1 in blood vessel function 
or in the regulation of BP have been described.
The regulation of BP is a complex physiological process 
that relies on the collaboration between the cardiovascular, neu-
ral, renal, and endocrine systems.28 In the endocrine system, the 
renin-Ang II (angiotensin II) system is the best known hormone 
cascade for the regulation of BP through the control of blood 
volume and vasoconstriction.29 In particular, AT1R (Ang II re-
ceptor 1) mediates the Ang II-induced vasoconstriction through 
the regulation of phosphorylation and dephosphorylation of 
MLC (myosin light chain), which directly affects the smooth 
muscle motility.30 AT1R stimulates GEF (guanine nucleotide 
exchange factor)-mediated GDP/GTP exchange of Rho (Ras 
homolog gene family), which activates ROCK (Rho kinase) 
through the conformational change followed by the inhibitory 
phosphorylation of MYPT1 (myosin phosphate target subunit 
1).30 MYPT1 composes MLCP (MLC phosphatase) with PP1cδ 
(protein phosphatase 1, catalytic subunit δ) and a small regulato-
ry subunit (M20).30 ROCK-mediated MYPT1 phosphorylation 
inactivates the phosphatase catalytic subunit PP1cδ, leading to 
sustained MLC phosphorylation. Contrary to MLCP, activa-
tory phosphorylation of MLCK (MLC kinase) phosphorylates 
MLC. When MLC is phosphorylated, in turn, vasoconstriction 
is stimulated, and BP is increased.30 Significantly increased 
Rho/ROCK activity and MYPT1 phosphorylation is observed 
Nonstandard Abbreviations and Acronyms
AMPK AMP-activated protein kinase
Ang II angiotensin II
AT1R angiotensin II receptor 1
BP blood pressure
CAG chicken β-actin promoter/enhancer coupled with the cyto-
megalovirus enhancer
CD36 cluster of differentiation 36
CTRP C1q/TNF-α–related protein
CTRP1 C1q/TNF-α–related protein 1
DBP diastolic blood pressure
Dex dexamethasone
ERK extracellular signal-related kinase
ET-1 endothelin-1
G-CSF granulocyte-colony stimulating factor
GAP GTPase-activating protein
GEF guanine nucleotide exchange factor
GLUT glucose transporter
GR glucocorticoid receptor
GRE glucocorticoid response element
IL-12 interleukin-12
IRS-1 insulin receptor substrate 1
KO knockout
MCP-1 monocyte chemoattractant protein 1
Mife mifepristone
MLC myosin light chain
MLCK MLC kinase
MLCP MLC phosphatase
MYPT myosin phosphate target
MYPT1 myosin phosphate target subunit 1
PKCα protein kinase Cα
PP1cδ protein phosphatase 1, catalytic subunit δ
Rho Ras homolog gene family
RhoA Ras homolog gene family, member A
ROCK Rho kinase
SBP systolic blood pressure
sm22α smooth muscle protein 22α
Novelty and Significance
What Is Known?
• Circulating CTRP1 (C1q/TNF-α [tumor necrosis factor-α]–related pro-
tein 1) is specifically expressed in the zona glomerulosa of the adrenal 
cortex and stimulates aldosterone production.
• CTRP1 is upregulated in both obese and hypertensive patients.
What New Information Does This Article Contribute?
• CTRP1 is an antihypotensive protein. During dehydration, the produc-
tion of CTRP1 increases in response to a glucocorticoid to prevent 
dehydration-induced hypotension.
• CTRP1 regulates blood pressure (BP) by stimulating the Rho (Ras ho-
molog gene family)/ROCK (Rho kinase)–signaling pathway to induce 
vasoconstriction.
In this study, we show that CTRP1 is an important regulator of BP. 
Using CTRP1 conditional KO (knockout) and TG (transgenic) mice, 
we show that the production of CTRP1 is increased on dehydra-
tion in response to glucocorticoid and that under these conditions, it 
prevents the decrease in BP. Moreover, we found that to increase BP, 
CTRP1 stimulated the membrane trafficking of AT1R (Ang II [angio-
tensin II] receptor 1) and Rho/ROCK, which leads to vasoconstriction. 
Because the Ctrp1 gene emerged at the time of the appearance of 
terrestrial vertebrates, when they were beginning to be exposed to 
dry conditions, we surmise that CTRP1 may have evolved to prevent 
dehydration-induced hypotension. These findings reveal a novel 
axis of BP regulation under dehydration conditions. Further studies 
of the CTRP1 signaling axis are likely to provide new understanding 
of the physiology of dehydration, as well as the pathological states 
associated with hemorrhage, diarrhea, and diabetes mellitus.
TG transgenic
TNF-α tumor necrosis factor-α
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in hypertensive patients, and this supports that the Rho/ROCK-
signaling pathway is highly related to the hypertension.31
In the present study, the physiological/pathophysiological 
function of CTRP1 in vascular Rho/ROCK-signaling pathway 
and BP regulation was elucidated using genetically modified 
mouse models, including CTRP1 conditional KO (knockout) 
and TG (transgenic) mice.
Methods
Detailed descriptions of experimental materials and methods used in 
this study are provided in the Online Data Supplement. The authors 
declare that all supporting data are available within the article and its 
Online Data Supplement.
Results
CTRP1 TG Mice Show a Hypertensive Phenotype
We have previously shown that CTRP1 is highly expressed in 
the zona glomerulosa of the adrenal gland and increases aldo-
sterone production.17 Thus, to determine whether CTRP1 is 
involved in BP control in vivo, CTRP1 TG mice were gener-
ated using Ctrp1 gene expression cassette under the control of 
the CAG (chicken β-actin promoter) as reported previously.16 
CTRP1 expression was significantly increased in various tis-
sues, as well as in serum (Figure 1A and 1B). Not only mono-
mers (≈35–40 kDa) but also multimers of CTRP1 (≈130–170 
kDa) were present in the sera of CTRP1 TG mice (Figure 1C).
Figure 1. CTRP1 (C1q/TNF-α [tumor necrosis factor-α]–related protein 1) TG (transgenic) mice showed a hypertensive phenotype. A, CTRP1 protein 
levels were analyzed in the indicated tissues from WT (wild type) and CTRP1 TG mice by immunoblotting. GAPDH protein levels were analyzed as a loading 
control. B, CTRP1 levels in sera from WT and CTRP1 TG mice were quantified by ELISA (n=8–12 per group). **P<0.01, 2-tailed Student t test. C, The native 
forms of serum CTRP1 were analyzed by immunoblotting. D, The blood pressure (BP) in 2 different lines of CTRP1 TG (lines 34 and 40), as well as WT 
mice, was measured using the tail-cuff method (n=6 per group). *P<0.05, **P<0.01, Dunnett test. E, BP in male and female CTRP1 TG mice was determined 
using the tail-cuff method. The male and female mice were age matched (n=4 per group). F, Age-dependent BP increases in CTRP1 TG and WT during the 
period from 1 to 12 mo of age were determined using the tail-cuff method (n=4–6 per group). *P<0.05 between CTRP1 TG and WT mice, 2-tailed Student 
t test. G and H, BP in CTRP1 TG and WT mice was measured using radiotelemetry (n=3–4 per group). Representative telemetric recordings of BP (G) and 
mean arterial pressure (MAP) during the day and night (H) are shown. I, Circulating CTRP1 levels in the sera of newly diagnosed patients with hypotension 
(n=8), hypertension (n=38), and healthy individuals (normotension, n=119) were measured by ELISA. *P<0.05, ***P<0.001, Tukey test. J, Pearson correlation 
coefficient between circulating CTRP1 levels in the sera and BP was calculated. All values are presented as mean±SD. DBP indicates diastolic blood 
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Next, tail-cuff BP monitoring was conducted to examine 
whether CTRP1 TG mice had increased BP. Systolic (SBP) 
and diastolic BP (DBP) were both increased in 2 indepen-
dent CTRP1 TG lines compared with WT (wild type) mice 
(Figure 1D). There were no differences in BP in CTRP1 TG 
mice from either sex (Figure 1E). The significant increase 
in BP in CTRP1 TG mice began at 6 to 10 months of age 
(Figure 1F). To further demonstrate the BP changes, CTRP1 
TG mice were implanted with radiotelemetry devices, and BP 
was monitored. BP and mean arterial pressure measured by 
telemetry were significantly higher in CTRP1 TG mice than in 
WT mice (Figure 1G and 1H). Circulating CTRP1 levels were 
also measured in genetic and surgical hypertension models. 
Circulating CTRP1 levels were highly increased in sera from 
spontaneous hypertensive rats compared with normotensive 
Wistar-Kyoto rats (Online Figure IIA), whereas no alterna-
tion of circulating CTRP1 levels was observed in the 2-kidney 
1-clip hypertensive rats compared with sham-operated normo-
tensive rats (Online Figure IIB and IIC). These results indicate 
that circulating CTRP1 levels would be differently affected by 
pathogenic causes of hypertension.
Furthermore, compared with normotensive healthy sub-
jects, newly diagnosed hypertensive patients showed statis-
tically increased circulating CTRP1 levels (Figure 1I), and 
circulating CTRP1 levels and BP showed the linear correla-
tion each other (Figure 1J).
Aged CTRP1 TG Mice Show Anatomic and 
Functional Alterations in the Heart
Next, we examined the effect of CTRP1 overexpression 
on cardiovascular and renal structures because histological 
alterations in those BP-related organs could be a cause of 
the BP increase. No alterations in thoracic aorta thickness 
were shown in 1-month-old CTRP1 TG mice. However, 
these significantly increased in 12.6-month-old CTRP1 
TG mice compared with age-matched WT mice (Online 
Figure IIIA). In addition, the left ventricular wall thick-
ness (Online Figure IIIB) and heart weights (Online Figure 
IIIC) were unaffected in 1-month-old CTRP1 TG mice but 
were increased in 12.6-month-old CTRP1 TG mice com-
pared with age-matched WT mice. Echocardiography re-
vealed that 12.6-month-old CTRP1 TG mice had impaired 
cardiac contractility as demonstrated by decreased ejection 
fractions and left ventricular fractional shortening, and in-
creased end-systolic volumes, left ventricular internal di-
mension in systole, and interventricular septal thickness 
at diastole (Figure 2A) without changes in left ventricular 
end-diastolic volume and left ventricular internal diameter 
end diastole. These alterations in the cardiovascular appara-
tus and echocardiographic parameters in aged CTRP1 TG 
mice are similar to those in cases of patients with chronic 
hypertension.32 Furthermore, 12.6-month-old CTRP1 TG 
mice showed renal hypertrophy (Online Figure IIID) and 
nephropathy, which included glomerulonephritis, vasculitis, 
and ectopic accumulation of unidentified vacuoles (Online 
Figure IIIE). On the contrary, other regulators of BP, in-
cluding Ang II, aldosterone, electrolytes (Na+, K+, Cl−), 
urine, and blood volume (Figure 2B through 2E), were not 
changed in CTRP1 TG mice compared with WT mice. The 
effect of CTRP1 on cardiac contraction was also examined. 
Either CTRP1 deficiency or excess conditions did not sig-
nificantly alter the phosphorylation of molecules involved 
in cardiac contractility, indicating that CTRP1 would not 
directly affect to cardiac contraction although CTRP1 could 
indirectly influence the cardiac function through prolonged 
BP increase (Online Figure IV).
We also found no circadian variation of BP in CTRP1 TG 
mice during day or night period (Figure 2F). Moreover, both 
transcription and translation levels of CTRP1 in various tis-
sues, as well as circulating CTRP1 levels, were not signifi-
cantly altered in WT mice during the day (Figure 2G through 
2I), indicating that CTRP1 is unlikely affected by the daily 
fluctuation of cortisol. Collectively, these findings indicate 
that morphological and functional impairments in the cardio-
vascular and renal tissues are secondary to CTRP1-induced 
chronic hypertension.
Dehydration-Induced Glucocorticoid Increased 
CTRP1 to Prevent BP Drop
Next, we asked which physiological conditions were associ-
ated with it. Considering that diabetic patients have highly in-
creased circulating CTRP1 levels,6–8 circulating CTRP1 levels 
were measured in streptozotocin-induced type I diabetic mice 
(Online Figure VA). Circulating CTRP1 levels were markedly 
increased (Figure 3A), but oral administration of glucose did 
not significantly further increase circulating CTRP1 levels 
(Online Figure VB), indicating that the increased circulating 
CTRP1 levels were not because of hyperglycemia in strepto-
zotocin-injected mice. Because streptozotocin-injected mice 
show frequent urination, we investigated whether dehydration 
in the diabetic mice may be a cause of the CTRP1 increase. 
To test this possibility, the water supply was limited for 2 days 
to induce dehydration conditions, and circulating CTRP1 
levels were measured. As a result, circulating CTRP1 levels 
were increased by 3-fold on day 2 after water restriction and 
recovered to normal levels when water supply was restored 
(Figure 3B). We next hypothesized that increased urination is 
related with the CTRP1-mediated BP increase. Surprisingly, 
WT mice remained normotensive and had a normal hemato-
crit during water restriction (Figure 3C; Online Figure VC), 
whereas CTRP1 CMV (cytomegalovirus)/β-actin–specific 
conditional KO mice (CTRP1ΔCAG) were hypotensive and 
failed to maintain normotension under water-restricted condi-
tions (Figure 3D), indicating that CTRP1 increases BP under 
dehydration conditions. To further test this hypothesis, WT 
mice were orally administered various diuretics to induce 
urine excretion-mediated dehydration. Consistent with the 
results from water restriction, the diuretic-treated WT mice 
showed highly increased circulating CTRP1 levels with a nor-
mal BP range (Online Figure VD and VE).
Norepinephrine and glucocorticoid hormones prevent 
BP decreases under dehydration conditions. To determine 
whether these hormones are associated with the CTRP1 in-
crease under dehydration conditions, mice treated with the 
diuretic triamterene (Triam) were concurrently treated with β-
adrenergic blocker propranolol or GR (glucocorticoid recep-
tor) blocker mifepristone (Mife). Combined treatment with 
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Figure 2. Aged CTRP1 (C1q/TNF-α [tumor necrosis factor-α]–related protein 1) TG (transgenic) mice show anatomic and functional alterations in 
the heart. A, Representative echocardiogram images and echocardiographic parameters from 12.6-mo-old WT (wild type) and CTRP1 TG mice (n=3 per 
group). *P<0.05, 2-tailed Student t test. B and C, Ang II (angiotensin II) and aldosterone (B) and electrolyte (C) levels in the sera from WT and CTRP1 TG mice were 
measured by ELISA or a blood chemistry analyzer (n=6–10 per group). D, WT and CTRP1 TG mice were individually housed in metabolic cages, and 24-h urine 
excretion was recorded (n=8–9 per group). E, Anticoagulated whole blood was collected from WT and CTRP1 TG mice by cardiac puncture and the hematocrit 
measured (n=3 per group). F, Blood pressure (BP) in WT and CTRP1 TG mice during the day and night was measured using radiotelemetry (n=3–4 per group). 
*P<0.05, **P<0.01, ***P<0.001, Tukey test. G and H, CTRP1 levels in the various tissues indicated were analyzed by qRT-PCR (quantitative real-time polymerase 
chain reaction) using 18S RNA for normalization (G) or by immunoblotting using β-actin for normalization (H; n=3 per group). I, Levels of CTRP1 in sera from WT 
mice over time were quantified by ELISA (n=3 per group). For all studies, mice were age matched. All values are presented as mean±SD. EDV indicates end-diastolic 
volume; EF, ejection fraction; ESV, end-systolic volume; FS, fractional shortening; IVSd, interventricular septal thickness at diastole; LVIDd, left ventricular internal 
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levels but not with propranolol (Figure 3E). Circulating cor-
ticosterone levels were also significantly increased along 
with circulating CTRP1 levels under the dehydration condi-
tions induced by streptozotocin injection, water restriction, 
and Triam administration (Online Figure VF through VH). 
In addition, the combined treatment of Triam with Mife re-
duced both SBP and DBP along with the CTRP1 decrease 
(Figure 3F), supporting that increased glucocorticoid signal-
ing is a key mediator of increased CTRP1 under dehydration 
conditions. To further prove this glucocorticoid-CTRP1 link, 
BP was monitored in CTRP1 TG mice after combined treat-
ment of Triam with Mife. In CTRP1 TG mice, BP was not 
affected by the Triam and Mife cotreatment (Figure 3G and 
3H). This is likely because of the excessive CTRP1 levels in 
CTRP1 TG mice. In the case of CTRP1ΔCAG mice, the basal 
BP level was decreased because of the low level of CTRP1 
(Figure 3H). Collectively, these findings reveal that the glu-
cocorticoid-mediated CTRP1 increase is a crucial factor for 
maintaining BP during dehydration.
Dexamethasone Directly Increases CTRP1 in the 
Skeletal Muscle
The positive regulation of CTRP1 by glucocorticoid was ad-
ditionally confirmed in electric foot shock-received mice. 
Circulating CTRP1 and glucocorticoid levels were simul-
taneously increased under electric foot shock conditions 
(Online Figure VIA and VIB). Moreover, CTRP1ΔCAG mice 
were less sensitive to increase in BP arising from elec-
tric foot shock compared with WT mice (Online Figure 
VIC), suggesting that CTRP1 regulates BP in response to 
glucocorticoid.
Next, we asked whether glucocorticoid directly increas-
es CTRP1 levels. To address this, WT mice were injected 
intraperitoneally with dexamethasone (Dex) or were given 
a restricted water supply. As a result, CTRP1 protein and 
mRNA expression levels were significantly increased in se-
rum, skeletal muscle, and heart after either Dex treatment 
or under the dehydration conditions (Figure 4A through 
4C). Because CTRP1 levels increased in the skeletal muscle 
Figure 3. CTRP1 (C1q/TNF-α [tumor necrosis factor-α]–related protein 1) contributes to glucocorticoid-mediated blood pressure (BP) control under 
dehydration conditions. A, CTRP1 levels in sera from WT (wild type) mice injected with streptozotocin (STZ; 120 mg/kg; n=4). **P<0.01, Tukey test. B and 
C, CTRP1 levels in sera (B) and BP (C) were determined in water-restricted mice using ELISA and the tail-cuff method, respectively (n=6 per group). **P<0.01, 
Tukey test. D, CTRP1ΔCAG mice were placed in a water-restricted environment, and BP was measured using the tail-cuff method at the indicated times (n=3–4 
per group). *P<0.05, between water restriction day +0 and day +2, Tukey test; #P<0.05, between WT and CTRP1ΔCAG mice, 2-tailed Student t test. E and F, 
WT mice were pretreated with propranolol (Prop; 10 mg/kg) or mifepristone (Mife; 0.1 mg/kg) 30 min before being orally administered with triamterene (Triam; 
60 mg/kg) for 2 d after which CTRP1 levels in the sera (E) and BP (F) were determined using ELISA and the tail-cuff method, respectively. Water was used as 
the vehicle control (n=6–8 per group). *P<0.05, **P<0.01, ***P<0.001, Tukey test. G and H, CTRP1ΔCAG, WT, and CTRP1 TG (transgenic) mice were pretreated 
with Mife (0.1 mg/kg) 30 min before being orally administered with Triam (60 mg/kg) for 2 d, after which CTRP1 levels in sera (G) and BP (H) were determined 
using ELISA and the tail-cuff method, respectively. Water was used as the vehicle control (n=6–8 per group). *P<0.05, **P<0.01, ***P<0.001, Tukey test. For 
all studies, mice were age matched. All values are presented as mean±SD. DBP/D indicates diastolic BP; N.S., no significant difference between the groups 
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in a time-dependent manner after Dex treatment, the skel-
etal muscle could be the main tissue that contributed to the 
CTRP1 increase by glucocorticoid (Figure 4D). To further 
examine this hypothesis, C2C12 myoblasts cells were dif-
ferentiated into myotubes and then treated with Dex. Both 
CTRP1 mRNA and protein levels were found to increase 
in a time-dependent manner after Dex treatment (Figure 4E 
and 4F), and furthermore CTRP1 secretion was also up-
regulated (Figure 4G) by Dex treatment. Additionally, 
Mife-mediated inhibition of glucocorticoid signaling abol-
ished the CTRP1 increase in the skeletal muscles under 
dehydration conditions, supporting the hypothesis that the 
main source of CTRP1 is the skeletal muscles under dehy-
dration conditions in response to glucocorticoid signaling 
(Online Figure VIIA and VIIB).
We next determined whether GR binds to the promoter 
region of Ctrp1 gene and performed ChIP-seq (chromatin 
immunoprecipitation sequencing) at Ctrp1 locus. GR oc-
cupancy was observed between exon 1 and exon 2 of Ctrp1 
gene. The active enhancer marker H3K27ac coincides ex-
actly with GR binding in this region (Figure 4H). Further 
analysis of this region revealed that there are 2 potential 
Figure 4. Dexamethasone (Dex) upregulates CTRP1 (C1q/TNF-α [tumor necrosis factor-α]–related protein 1) expression in the skeletal muscle. A, 
Changes in the levels of CTRP1 in sera over time from WT (wild type) mice injected (intraperitoneal [I.P.]) with Dex (10 mg/kg; n=4 per group). *P<0.05, Tukey 
test. B and C, WT mice were injected (I.P.) with Dex (10 mg/kg) and kept for 6 h, or were dehydrated (DeHy) for 2 d, after which CTRP1 levels in the various 
tissues indicated were analyzed by immunoblotting using β-actin for normalization (B) or by qRT-PCR (quantitative real-time polymerase chain reaction) 
using 18S RNA for normalization (C; n=3–5 per group). *P<0.05, **P<0.01, Tukey test. D, Time course of changes in CTRP1 levels in the skeletal muscle 
from WT mice injected (I.P.) with Dex (10 mg/kg; n=3 per group) and analyzed by immunoblotting for CTRP1 expression using β-actin for normalization. The 
immunoblot (top) and quantification of the CTRP1/β-actin ratio (bottom) are shown. *P<0.05, **P<0.01, Dunnett test. E–G, Fully differentiated C2C12 myotubes 
were treated with Dex (2 μM) for the indicated times, and the CTRP1 levels were analyzed by qRT-PCR (E) and immunoblotting (F). Culture media (CM) was 
collected, and CTRP1 protein levels were analyzed by immunoblotting (G, bottom) and ELISA (G, top). β-actin levels and 18S RNA levels were used as loading 
controls for the immunoblot and the qRT-PCR analysis, respectively. *P<0.05, **P<0.01, ***P<0.001, Dunnett test. H, Identification of the GR (glucocorticoid 
receptor)-binding site in the Ctrp1 intron region. Genome browser snapshot of GR and H3K27ac at Ctrp1 locus. The frame with solid line and dashed line refer 
to the putative promoter region and intronic enhancer co-occupied with GR binding, respectively. I, Locations and sequences of the potential glucocorticoid 
response elements (GREs) in the Ctrp1 intron region. J, The effect of Dex on activity of predictive GRE region. HEK-293T were pretreated with mifepristone (20 
μM) 30 min before Dex treatment (2 μM), and firefly luminescence was determined. Mice were age matched for in vivo study. **P<0.01, ***P<0.001, Tukey test. 
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glucocorticoid response elements (GREs) within the intron 
region of Ctrp1 gene, which showed high homology be-
tween mouse and human (71%; Figure 4I; Online Figure 
VIII). To find out whether the potential GREs are func-
tional, human GRE-containing region was cloned and li-
gated at the downstream of a putative human Ctrp1 gene 
promoter region, and reporter assays were performed. 
Solely GRE was not enough to increase the luciferase ac-
tivity by Dex, but the putative promoter GRE showed a 
significantly increased luciferase activity by Dex, which 
was strongly suppressed by Mife (Figure 4J). Solely puta-
tive promoter was also responsive to dexamethasone but 
not affected by Mife (Figure 4J). These data support the 
notion that CTRP1 is directly increased by dehydration-
induced glucocorticoid.
CTRP1 Increases BP Through Vascular Rho/ROCK 
Activation
Next, to explore the molecular mechanism by which CTRP1 
increases BP, we determined whether CTRP1 directly induces 
aortic contraction because vascular contractility is a crucial 
in BP upregulation and the development of hypertension. 
Endothelium-intact thoracic aortas isolated from Sprague 
Dawley rats were treated with CTRP1, and its contractile ef-
fect was monitored for 60 minutes. As a result, CTRP1 in-
creased the contractile force of the aorta 1 to 5 minutes after 
treatment (Figure 5A), and this effect was dose dependent and 
comparable with that of 5 μM of Ang II (Figure 5B), implying 
that CTRP1 increases BP via vasoconstriction.
To identify the downstream signaling pathway by which 
CTRP1 induces vasoconstriction, MLC phosphorylation was 
Figure 5. CTRP1 (C1q/TNF-α [tumor necrosis factor-α]–related protein 1) induces vasoconstriction through the RhoA (Ras homolog gene family, 
member A)/ROCK (Rho kinase)-signaling pathway. A, The time course contraction of thoracic aortic rings isolated from Sprague Dawley rats measured 
after CTRP1 treatment (40 ng/mL). The contractile activity of CTRP1 is shown both as a bar graph (bottom) and a physiogram (top, inset). The dot in the 
physiogram (see arrow) indicates the moment of addition of CTRP1. *P<0.05, **P<0.01, Dunnett test. B, Dose-dependent contraction of thoracic aortic rings 
isolated from Sprague Dawley rats in response to CTRP1 treatment (left) and quantification of the areas under curve (AUCs; right). Ang II (angiotensin II) was 
used as a positive vasoconstrictor. ***P<0.001, Tukey test. C, The levels of vasoconstriction-related proteins in MOVAS after CTRP1 treatment (1 μg/mL) were 
analyzed using immunoblotting. β-actin protein levels were used as the loading control. D, Dose-dependent changes in the levels of p-MLC and p-MYPT1 
in MOVAS 30 min after CTRP1 treatment by immunoblotting. β-actin protein levels were analyzed as a loading control. E, Levels of the indicated proteins in 
the skeletal muscle or aorta from WT (wild type) and CTRP1ΔCAG mice were analyzed by immunoblotting (left) and their ratios with respect to their total levels 
were quantified (right; n=5). *P<0.05, 2-tailed Student t test. F, MOVAS were pretreated with the Rho/ROCK pathway inhibitor Y-27362 (30 μM) 30 min before 
CTRP1 treatment (1 μg/mL), and p-MLC levels were analyzed by immunoblotting 60 min after CTRP1 treatment (top). Quantification of the p-MLC/MLC 
(myosin light chain) ratio is shown (bottom). **P<0.01, Tukey test. G, WT and CTRP1 TG (transgenic) mice were orally administered with Y-27362 (25 mg/kg), 
and blood pressure (BP) was measured using the tail-cuff method at the indicated times (n=5–6 per group). **P<0.01, between 0 h and indicated hours after 
Y-27632 administration in CTRP1 TG mice, Dunnett test. Mice or rats were age matched for the in vivo study. All values are presented as mean±SD. DBP 
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examined in the mouse aorta cell line, MOVAS. CTRP1 treat-
ment increased MLC phosphorylation (active form) without 
any effect on MLCK phosphorylation (active form), whereas 
it increased MYPT (myosin phosphate target) phosphoryla-
tion (inactive form; Figure 5C). These effects of CTRP1 on 
MYPT1 and MLC phosphorylation were dose dependent 
(Figure 5D), and furthermore, CTRP1ΔCAG mice showed a de-
crease in the basal levels of MYPT1 and MLC phosphorylation 
(Figure 5E), indicating that CTRP1-induced MYPT1 inactiva-
tion contributes to MLC activation. Next, we examined whether 
Rho/ROCK-signaling pathway, which is an upstream kinase 
pathway of MLC, could affect CTRP1-induced BP upregula-
tion. The ROCK inhibitor Y-27632 and thiazovivin treatment 
completely blocked CTRP1-induced MLC phosphorylation in 
MOVAS (Figure 5F; Online Figure IX), and oral administra-
tion of Y-27632 effectively decreased SBP without a significant 
change in DBP in CTRP1 TG mice, with BP returning to hyper-
tensive state 24 hours after medication (Figure 5G). Collectively, 
these findings demonstrate that CTRP1 upregulates BP via Rho/
ROCK-signaling pathway–induced vasoconstriction.
Given that CTRP1 mainly targets the aorta, next, we gen-
erated vascular smooth muscle-specific CTRP1 conditional 
KO mice (CTRP1Δsm22α; Online Figure XA). CTRP1Δsm22α 
mice were normotensive and did not show any changes in cir-
culating CTRP1 levels (Online Figure XB and XC), whereas 
CTRP1ΔCAG mice showed a drop in BP along with a decrease 
in circulating CTRP1. This data imply that CTRP1 increases 
BP in an endocrine manner.
CTRP1 Stimulates the Rho/ROCK-Signaling 
Pathway by Enhancing Trafficking of the AT1R to 
the Plasma Membrane
Because Ang II activates the Rho/ROCK-signaling pathway, 
and we have previously shown that the CTRP1-signaling path-
way is partially blocked by the AT1R blocker losartan,17 we 
examined whether losartan inhibits the CTRP1-induced Rho/
ROCK-signaling pathway. CTRP1-induced MYPT1 and MLC 
phosphorylation was effectively blocked by losartan in MOVAS 
(Figure 6A). Losartan treatment also decreased BP in CTRP1 
TG mice, but BP completely and rapidly rebounded after losar-
tan treatment was stopped (Figure 6B). Furthermore, Ang II-
infused CTRP1ΔCAG mice were less sensitive to Ang II-mediated 
BP increase compared with WT mice, and BP in CTRP1 TG 
mice was not significantly altered by continuous Ang II infusion 
because of enforcedly produced CTRP1 (Figure 6C), indicating 
that signaling through AT1R is an important effector mecha-
nism in CTRP1-mediated vasoconstriction and the resulting 
BP increase. To further dissect the molecular mechanism, the 
interaction between CTRP1 and AT1R was assessed by cross-
linking and coimmunoprecipitation, but no physical interaction 
between CTRP1 and AT1R was observed (Online Figure XIA 
and XIB). The mRNA levels of AT1Rα and AT1Rβ were also 
unchanged in aortas isolated from CTRP1 TG mice (Online 
Figure XIC through XIE). Next, we assessed whether CTRP1 
stimulates trafficking of AT1R to the plasma membrane because 
receptor movement to the plasma membrane is able to sensitize 
signaling pathways. Live MOVAS imaging revealed that the 
EGFP-AT1R trafficked to the plasma membrane 5 minutes after 
CTRP1 treatment and then returned to the cytosol (Figure 6D). 
An immunoblot assay also showed CTRP1-induced AT1R 
plasma membrane trafficking (Figure 6E). To examine whether 
AT1R movement affects CTRP1-induced Rho/ROCK activa-
tion, EGFP-AT1R–transfected MOVAS were pretreated with 
the Golgi apparatus disruptor brefeldin A. Brefeldin A pretreat-
ment completely interrupted CTRP1-induced AT1R membrane 
trafficking (Figure 6F), as well as CTRP1-induced MYPT1 
and MLC phosphorylation (Figure 6G). Furthermore, CTRP1 
TG mice showed significantly increased membranous AT1R in 
aortas compared with WT mice, and 2-hour oral administration 
of Y-27632 reduced membranous AT1R in CTRP1 TG mice to 
level of WT mice (Figure 6H). On the contrary, administration 
of Y-27632 decreased the membranous Na+/K+ ATPase, and 
this is probably because Rho activation stimulates the mem-
brane trafficking of Na+/K+ ATPase.33,34 These results imply that 
CTRP1 activates Rho/ROCK-signaling pathway by enhancing 
AT1R membrane trafficking, leading to increase in BP.
CTRP1 Enhances AT1R Plasma Membrane 
Trafficking Through Phosphorylation of AKT and 
AS160
Next, we asked how CTRP1 stimulates AT1R plasma mem-
brane trafficking. Given that CTRP1 stimulates GLUT (glucose 
transporter) 4 movement to the plasma membrane through ac-
tivation of AKT-signaling pathway in C2C12 myotubes,16 we 
first examined whether CTRP1 is able to activate AKT substrate 
of 160 kDa (AS160) via phosphorylation in MOVAS. CTRP1 
treatment increased phosphorylation of AKT at T308 and S437 
and phosphorylation of AS160 at T642 and S588 without alter-
ing the total levels of these 2 signaling proteins (Figure 7A). 
Furthermore, treatment with an AKT inhibitor reduced not 
only CTRP1-induced AKT and AS160 phosphorylation but 
also MYPT1 and MLC phosphorylation in a dose-dependent 
manner (Figure 7B). Moreover, AKT inhibition remarkably 
reduced CTRP1-induced AT1R plasma membrane trafficking 
(Figure 7C). Consistent with those findings, CTRP1-induced 
phosphorylation of MYPT1 and MLC was significantly de-
creased in AS160-depleted MOVAS compared with MOVAS 
transfected with a control siRNA (Figure 7D). Furthermore, live 
cell imaging (Figure 7E) and an immunoblot assay of plasma 
membrane fractions (Figure 7F) showed that depletion of AS160 
attenuated CTRP1-induced AT1R plasma membrane trafficking 
in MOVAS. In addition to the results from in vitro assay, aortas 
isolated from CTRP1 TG mice showed an increase in the phos-
phorylation of AKT and AS160, as well as in the phosphoryla-
tion of MYPT1 and MLC (Figure 7G). These in vitro and in vivo 
results clearly support the fact that CTRP1-induced AT1R mem-
brane trafficking through AS160 is the key event that occurs to 
activate Rho/ROCK downstream signaling leading to vasocon-
striction. On the contrary, inhibition of ERK (extracellular sig-
nal-related kinase) and cAMP,30 which are known to be signaling 
molecules that can crosstalk with AT1R and regulate its activity, 
was not associated with CTRP1-induced AT1R translocation to 
the cell surface (Online Figure XII).
Discussion
Ctrp1 gene could be considered as a hypotension-resistant 
gene because CTRP1 increased BP against dehydration-
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shows that Ctrp1 genes arise at the time of the emergence 
of vertebrates and are conserved in Euteleostomi (Online 
Figure XIIIA). In particular, human Ctrp1 gene is more 
homologous to terrestrial than aquatic vertebrates (Online 
Figure XIIIB). In the transition from aquatic to terrestrial 
life, vertebrates become exposed to the hot, dry, and windy 
environments in which conditions vertebrates should con-
trol body temperature by sweating; however, continuous 
and excessive dehydration by sweating can cause the loss 
of body fluid and salts leading to hypotension.35,36 Thus, we 
deduce that Ctrp1 gene is likely to be evolved to prevent 
dehydration-induced hypotension.
Figure 6. The CTRP1 (C1q/TNF-α [tumor necrosis factor-α]–related protein 1)-activated Rho (Ras homolog gene family)/ROCK (Rho kinase)-
signaling pathway is associated with AT1R (Ang II [angiotensin II] receptor 1) translocation. A, MOVAS were pretreated with losartan (100 μM) 30 min 
before Ang II (500 nmol/L) or CTRP1 (1 μg/mL) treatment for the indicated times. The levels of the indicated proteins were examined by immunoblotting. B, 
CTRP1 TG (transgenic) and WT (wild type) mice were orally administered with losartan (1 mg/mL) for 7 d, after which blood pressure (BP) measurements 
were determined using the tail-cuff method (n=8–10 per group). The arrowheads indicate the day on which losartan administration was stopped. *P<0.05, 
**P<0.01 between 0 d and indicated days after losartan administration in CTRP1 TG mice, Dunnett test. C, WT, CTRP1ΔCAG, and CTRP1 TG mice were 
implanted subcutaneously with osmotic pumps containing Ang II (1 μg/kg per min), and BP was determined using the tail-cuff method for 14 d (n=4 per 
group). D, MOVAS were transfected with pEGFP-AT1R and EGFP-expressing cells were monitored after CTRP1 treatment (1 μg/mL) using live imaging 
microscopy. The arrows indicate the expression of AT1R on cell surfaces or long membrane process (scale bar=5 μm). E, MOVAS were treated with CTRP1 
(1 μg/mL), after which the cells were fractionated and the cytosol and plasma membrane were isolated. The expression levels of AT1R were examined by 
immunoblotting. The protein expression levels of α-tubulin and Na+/K+ ATPase were analyzed as loading controls for the cytosolic and plasma membrane 
fractions, respectively. F and G, MOVAS were pretreated with brefeldin A (10 µg/mL) 30 min before a 20-min treatment with Ang II (500 nmol/L) or CTRP1 
(1 μg/mL). The cells were immunostained for AT1R (F, top) or rabbit IgG (F, bottom) to determine its localization (scale bar=5 μm), and the levels of the 
indicated protein were analyzed by immunoblotting (G). H, WT and CTRP1 TG mice were orally administered with Y-27362 (25 mg/kg; n=4) for 2 h, after 
which cytosolic and membranous AT1R were examined in aortas by immunoblotting. The protein expression levels of α-tubulin and Na+/K+ ATPase were 
analyzed as loading controls for the cytosolic and plasma membrane fractions, respectively. 4′,6-diamidino-2-phenylindole (DAPI) was used to counterstain 
DNA for immunofluorescence, and β-actin protein levels were measured as a loading control for immunoblotting. Mice were age matched for in vivo study. All 
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Decrease in BP in response to dehydration can trigger 
signaling processes to restore BP, which is exerted through 2 
temporal mechanisms. One is a short-term mechanism, which 
regulates blood vessel diameter, heart rate, and contractility. 
This short-term regulation is exerted by sympathetic nervous 
system, which secretes epinephrine/norepinephrine from the 
adrenal gland.29 The other is a long-term mechanism, which is 
accomplished by the renal-dependent renin-Ang II (angioten-
sin II) system activity and renal-independent glucocorticoid 
secretion.29 In the present study, we provide evidence that 
Figure 7. CTRP1 (C1q/TNF-α [tumor necrosis factor-α]–related protein 1) induces AT1R (Ang II [angiotensin II] receptor 1) translocation through the 
AKT/AS160-signaling pathway. A, The levels of phosphorylated AKT and AS160 in MOVAS were analyzed using immunoblotting after CTRP1 treatment (1 
μg/mL) for the indicated times. The β-actin protein levels were analyzed as a loading control. B, MOVAS were pretreated with the indicated concentrations 
of AKTi (AKT inhibitor) 30 min before a 5-min treatment with CTRP1 (1 μg/mL), and the levels of the indicated protein/phosphoproteins were analyzed by 
immunoblotting. β-actin protein levels were analyzed as a loading control. C, MOVAS were pretreated with AKTi (10 μM) 30 min before treatment of CTRP1 
(1 μg/mL) for the indicated times, and cytosolic and plasma membrane fractions were isolated. The expression levels of the AT1R were then examined by 
immunoblotting. α-tubulin and Na+/K+ ATPase protein levels were analyzed as loading controls for the cytosolic and plasma membrane fractions, respectively. 
D–F, Three small interfering RNAs (siRNAs) against different regions of AS160 were designed and MOVAS were transfected with these AS160 siRNAs or a 
control siRNA (20 nmol/L) for 48 h. D, Levels of the indicated proteins/phosphoproteins in MOVAS were analyzed by immunoblotting in the siRNA-transfected 
cells after CTRP1 treatment (1 μg/mL) for the indicated times. β-actin protein levels were analyzed as a loading control. E, MOVAS cells transfected with the 3 
siRNAs were transfected with pEGFP-AT1R, and cells harboring GFP (green fluorescent protein) were monitored at the indicated times after CTRP1 treatment 
(1 μg/mL) using live imaging microscopy. The arrows indicate expression of AT1R on the cell surface (scale bar=5 μm). F, The siRNA-transfected cells were 
treated with CTRP1 (1 μg/mL), and cytosolic and plasma membrane fractions were isolated, after which the expression levels of AT1R were examined by 
immunoblotting. α-tubulin and Na+/K+ ATPase protein levels were analyzed as loading controls for the cytosolic and plasma membrane fraction, respectively. 
G, The expression levels of the indicated phosphoproteins were examined in aortas from WT (wild type) and CTRP1 TG (transgenic) mice by immunoblotting 
(left), and their ratio to total protein levels were quantified (right; n=3 per group). The β-actin protein levels were analyzed as a loading control. All mice were 
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CTRP1 acts as a novel long-term BP regulator through the 
following experimental evidence: (1) dehydration increases 
CTRP1 production, (2) a synthetic glucocorticoid directly 
increases CTRP1 production, (3) a glucocorticoid antagonist 
reduces dehydration-induced CTRP1 levels, (4) CTRP1ΔCAG 
mice are not able to maintain BP under dehydration condi-
tions, and (5) CTRP1 production is increased 2 days after 
mice are placed under dehydration conditions. Attenuated 
BP increase in electric foot shock-received CTRP1ΔCAG mice 
supports that CTRP1 is a key effector of glucocorticoid-me-
diated BP regulation. This result also implies that CTRP1 can 
regulate BP under other conditions that increase glucocorti-
coid. Nonetheless of glucocorticoid secretion is stimulated by 
sympathetic nervous system, CTRP1 is likely to be regulated 
by hormonal stimulation because glucocorticoid increases 
CTRP1 at long term.
It is thought that skeletal muscle is passively involved 
in BP regulation by mechanical blood vessel contraction.37 
However, here, we provide evidence that muscle is actively 
engaged in BP regulation through CTRP1 production in re-
sponse to dehydration and glucocorticoid secretion. Thus, 
CTRP1 could be classified as a novel myokine along with 
CTRP15, which is specifically expressed in the skeletal 
muscle and participates in lipid metabolism and autophagy.38 
Moreover, CTRP1Δsm22α mice showed an intact circulating 
CTRP1 level, indicating that a major source of circulating 
CTRP1 is the skeletal muscle. On the contrary, circulating 
cortisol levels were not significantly altered in hypertensive 
patients compared with normotensive individuals and also 
did not show correlation with CTRP1 (Online Figure XIVA 
and XIVB). We speculate that this contradictory result might 
be because of the inconsistency between local and systemic 
concentration of cortisol. CTRP1 could be increased by local 
cortisol within skeletal, heart, and aorta muscles instead of 
systemic cortisol because myotubes express 11-β hydroxys-
teroid dehydrogenase, which converts biologically inert cor-
tisone to biologically active cortisol.39
Dehydrated CTRP1ΔCAG mice and ROCK inhibitor-treated 
CTRP1 TG mice showed more sensitive changes in SBP than 
in DBP. Given that CTRP1 acts as a vasoconstrictor, a sensi-
tive change in SBP change is logical because SBP is more 
responsive to vasoconstrictors than DBP.40,41 On the contrary, 
it is unlikely that the CTRP1-mediated BP increase is asso-
ciated with endothelium-dependent vasorelaxation not only 
because CTRP1 was poorly expressed in epithelial cells but 
also because endothelium-denuded aortic rings isolated from 
CTRP1ΔCAG KO mice were less contracted by Ang II compared 
with those from WT mice, although aortic rings from mice 
poorly response to Ang II compared with aortic rings from 
rats42 (Online Figure XVA and XVB).
Rho/ROCK negatively regulates eNOS (endothelial NO 
synthase)/NO signaling.43 However, CTRP1 is likely to in-
duce vasoconstriction through eNOS/NO-independent mech-
anism because CTRP1 treatment did not significantly alter 
the levels of NO, eNOS, and phosphorylation of eNOS at 
S1177 in aortic rings isolated from WT mice (Online Figure 
XVC and XVD). In addition, either CTRP1 deficiency or 
excess did not affect the eNOS mRNA levels in the aortas 
(Online Figure XVE), and no significant alterations of total 
and phosphorylated eNOS were observed in those mice under 
dehydration conditions (Online Figure XVF). Furthermore, 
CTRP1 did not affect the production of NO in MOVAS cells 
(Online Figure XVG).
In this study, we found that CTRP1 increases MYPT1 
phosphorylation through activation of the Rho/ROCK-
signaling pathway and that CTRP1-induced Rho/ROCK acti-
vation depends at least on AT1R. In aortas, membranous AT1R 
and cytosolic MLC phosphorylation were increased under de-
hydration condition and returned to normal levels by rehydra-
tion, which are similar to the fluctuation of CTRP1 level under 
water restriction conditions, indicating that CTRP1, plasma 
membrane trafficking of AT1R, and MLC phosphorylation 
closely cross talk each other to regulate BP under dehydra-
tion conditions (Online Figure XVI). The attenuated BP up-
regulation in Ang II-implanted CTRP1ΔCAG mice also supports 
the fact that CTRP1 is required for activation of the Ang II/
AT1R-signaling pathway, even though further studies are re-
quired to elucidate the fine molecular mechanisms by which 
CTRP1 and Ang II cooperatively or independently regulate 
BP. Because the receptor for CTRP1 has not yet been iden-
tified, we hypothesize that CTRP1-stimulated AT1R plasma 
membrane trafficking itself could sensitize AT1R, which is 
easily activated by a small amount of Ang II.
Nonetheless, we provide a mechanism by which CTRP1 
stimulates AT1R plasma membrane trafficking. AS160 was 
identified as an AKT substrate in the adipose tissue and 
contains a Rab-GAP (GTPase-activating protein) domain 
at its COOH terminus and multiple AKT phosphoryla-
tion sites.44 Phosphorylation of these sites by AKT stimu-
lates GLUT4 translocation toward the cell membrane in 
adipocytes and myocytes in response to insulin.44,45 Newly 
identified evidence has shown that AKT/AS160 signaling 
regulates the plasma membrane trafficking of various recep-
tors in various tissues and cell types, including GLUT1,46,47 
GLUT8,48,49 aquaporin 2,50,51 β1-integrin,52 CD36 (cluster of 
differentiation 36),53,54 epithelial Na+ channel,55 potassium 
voltage-gated channel Kv1.5,56 and Na+/K+ ATPase.57,58 In 
this study, we show for the first time that AS160 is activated 
by the CTRP1-AKT axis, leading to AT1R plasma mem-
brane trafficking. This new finding is supported by the evi-
dence that treatment with an AKT inhibitor, or knockdown 
of AS160 in MOVAS, markedly inhibits CTRP1-induced 
Rho/ROCK activation associated with attenuated AT1R 
plasma membrane trafficking. In addition, CTRP1 TG mice 
showed high levels of phosphorylated AKT and AS160 
in the aorta, and we have previously shown that CTRP1 
increases GLUT4 translocation to the plasma membrane 
through AKT phosphorylation at S473.16 On the contrary, 
because multitargeted tyrosine kinase inhibitors sorafenib 
and sunitinib effectively suppressed CTRP1-induced phos-
phorylation of AKT, AS160, MYPT1, and MLC, we sug-
gest that CTRP1 transmits the signal into AKT through a 
tyrosine kinase (Online Figure XVII).
The translocation of RhoA and PKCα (protein kinase 
Cα) to the plasma membrane positively regulates the vaso-
constriction in response to Ang II.59 Interestingly, CTRP1 
increased the plasma membrane trafficking of RhoA and 
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the phosphorylation of PKCα at S657, which is an in-
dication of PKCα activation60 (Online Figure XVIIIC). 
Moreover, pharmacological PKCα inhibition abolished 
CTRP1-induced p-MYPT1, p-MLC, p-AKT at S473, and 
p-AS160 at S588 (Online Figure XVIIID). These results 
show that PKCα is also involved in CTRP1-induced acti-
vation of Rho/ROCK-signaling pathway although marginal 
alteration was observed in aortas from CTRP1ΔCAG, WT, and 
TG mice (Online Figure XVIIIE). On the contrary, it is also 
possible that hypertensive phenotype of CTPR1 TG mice is 
affected by changes in cytokines, chemokine, and growth 
factors. CTRP1 TG mice showed a significant increase in 
circulating G-CSF (granulocyte-colony stimulating factor), 
active IL-12 (interleukin-12) heterodimer (IL-12 P40/p70), 
MCP-1 (monocyte chemoattractant protein 1), and TNFR1 
(tumor necrosis factor receptor 1) without changes in cir-
culating and transcription levels of ET-1 (endothelin-1) in 
aortas, which is well-known vasoconstrictor,61 indicating 
that CTPR1-mediated BP increase is ET-1 independent, but 
role of cytokines increased in CTRP1 TG mice remains to be 
studied (Online Figure XIXA through XIXC).
We showed that CTRP1 is increased in hypertensive 
patients, implying the pathophysiological role of CTRP1 
in hypertension. Aged CTRP1 TG mice also showed simi-
lar histological impairments to hypertensive patients who 
show the left ventricular hypertrophy and renal structure 
failure,62 suggesting that abnormal production of CTRP1 
is a novel pathogenesis for hypertension. Furthermore, 
clinical data showed that circulating CTRP1 levels are 
not related to sex although they were positively correlated 
with age (Online Figure XXA and XXB). In addition, cir-
culating CTRP1 levels in hypertensive patients medicated 
with calcium channel blockers or AT1R blockers were 
similar with those in normotensive individuals (Online 
Figure XXI). To obtain a more comprehensive conclusion, 
CTRP1 and BP measurements before and after medication 
in a newly diagnosed hypertensive patient are absolutely 
needed. Nonetheless, the limitation of this clinical data 
analysis was that CTRP1 values were not normalized by 
diuretic medication, circulating glucocorticoid levels, or 
blood volume status, and this should be addressed in a fu-
ture study.
Figure 8. Proposed role of CTRP1 (C1q/TNF-α [tumor necrosis factor-α]–related protein 1) in the blood pressure (BP)-regulatory mechanism under 
dehydration conditions. Under dehydration conditions, CTRP1 increases in response to glucocorticoid. CTRP1 activates AKT by phosphorylation, and AKT 
inactivates AS160 by phosphorylation. This positively stimulates AT1R plasma membrane trafficking and its downstream Rho (Ras homolog gene family)/ROCK 
(Rho kinase)–signaling pathway. Inactivation of MYPT1 (myosin phosphate target subunit 1) by phosphorylation sustains MLC (myosin light chain) phosphorylation, 




 http://ahajournals.org by on O
ctober 5, 2018
e18  Circulation Research  August 17, 2018
In summary, we have identified a novel role of CTRP1 
in the long-term, nonrenal-mediated upregulation of BP 
that occurs under dehydration conditions (Figure 8). In this 
mechanism, dehydration-induced glucocorticoid increases 
CTRP1, which activates AKT/AS160-mediated AT1R move-
ment to the plasma membrane. This leads to AT1R sensitiza-
tion and activation of its downstream Rho/ROCK-signaling 
pathway, which sustains the MLC phosphorylation leading to 
vasoconstriction.
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